Severe asthma: Why targeted therapies miss some Type 2 patients

Severe asthma, by definition, is a form of asthma that requires high-dose inhaled corticosteroids (ICS) plus a second controller, or systemic corticosteroids, to prevent it from becoming 'uncontrolled,' or which remains uncontrolled despite this therapy. This patient population, representing approximately 5-10% of all asthma cases, accounts for a disproportionately high burden of healthcare resource utilization, including emergency department visits and hospitalizations. The hallmark of Type 2 severe asthma is an inflammatory cascade driven by cytokines such as IL-4, IL-5, and IL-13, often characterized by elevated eosinophil counts in blood or sputum, and increased fractional exhaled nitric oxide (FeNO).

For decades, the conventional understanding of asthma pathophysiology has largely concentrated on the large and medium-sized airways, where bronchoconstriction and inflammation are readily observed and targeted by inhaled therapies. Spirometry, the cornerstone of asthma assessment, primarily reflects airflow obstruction in these larger airways. But the lung's architecture is far more complex, with a vast network of smaller, distal airways (less than 2 mm in diameter) that contribute significantly to total airway resistance and gas exchange. These distal airways, often termed the 'silent zone' due to their limited contribution to standard spirometric measurements, are now drawing increased attention in severe asthma.

The Overlooked Anatomy of Inflammation

The distal airways, including the respiratory bronchioles and alveolar ducts, possess distinct immunological and structural characteristics compared to their proximal counterparts. They are lined by a different epithelial cell type, have fewer smooth muscle cells, and are more prone to irreversible remodeling, such as fibrosis and fixed airway obstruction. In Type 2 severe asthma, this region can become a significant reservoir of inflammatory cells, including eosinophils, mast cells, and T-helper 2 (Th2) lymphocytes, even when inflammation in the larger airways appears to be adequately controlled. This persistent inflammation in the distal lung can drive ongoing symptoms, contribute to frequent exacerbations, and lead to progressive lung function decline.

The challenge in assessing distal airway involvement lies in its inaccessibility to routine clinical tools. Bronchoscopy with bronchoalveolar lavage (BAL) or transbronchial biopsy can provide direct insights, but these are invasive procedures not suitable for routine monitoring. Imaging techniques, such as high-resolution computed tomography (HRCT) with quantitative analysis, are beginning to offer non-invasive ways to visualize distal airway changes, including air trapping and wall thickening. But these methods are not yet standard practice for routine asthma management. The focus on airways beyond the proximal is a growing area of interest.

Biomarkers and Therapeutic Implications

The recognition of distal airway pathology has profound implications for understanding biomarker profiles and optimizing therapeutic strategies in Type 2 severe asthma. While peripheral blood eosinophil counts and FeNO are established biomarkers for Type 2 inflammation, their correlation with distal airway inflammation is not always straightforward. A patient might have elevated systemic Type 2 markers, yet still experience persistent symptoms due to localized, poorly controlled inflammation in the distal lung that is not fully reflected by these systemic measures. This disconnect can explain why some patients with high Type 2 biomarkers do not respond optimally to biologics targeting proximal airway inflammation.

Targeting Type 2 inflammation with biologics has revolutionized severe asthma management. Therapies such as anti-IL-5, anti-IL-4Rα, and anti-IgE antibodies have demonstrated significant efficacy in reducing exacerbations and improving lung function in carefully selected patient populations. But even with these advanced treatments, a subset of patients continues to experience uncontrolled disease. This persistent lack of control may be partly attributable to the inability of current therapies to adequately penetrate or resolve inflammation in the distal airways. The pharmacokinetics and pharmacodynamics of inhaled and injectable biologics in the distal lung are complex and not fully elucidated. For example, some biologics may have preferential distribution to larger airways, leaving distal inflammation relatively untouched. This is a key question that has been raised about why benralizumab patients still suffer asthma attacks.

The structural changes in the distal airways, including airway remodeling, fibrosis, and mucus plugging, can also create a physical barrier to drug delivery. These changes can lead to ventilation-perfusion mismatch and contribute to the overall burden of disease. Current treatment guidelines for severe asthma emphasize a stepwise approach, escalating therapy based on symptom control and exacerbation frequency. But these guidelines do not explicitly differentiate between proximal and distal airway involvement, largely due to the diagnostic challenges. The Oxford Handbook of Respiratory Medicine provides a comprehensive overview of current management strategies, but the distal airway focus is still emerging.

Unmet Needs and Future Directions

The unmet need in Type 2 severe asthma, particularly for patients with persistent distal airway inflammation, is substantial. These patients often experience a poorer quality of life, higher rates of exacerbations, and accelerated lung function decline. Developing novel diagnostic tools that can non-invasively and accurately assess distal airway inflammation is a critical step forward. Techniques like forced oscillation technique (FOT) and nitrogen washout tests offer some promise in detecting small airway dysfunction, but their clinical utility in guiding specific therapeutic choices for distal airway inflammation in severe asthma is still under investigation.

Future therapeutic strategies may need to consider drug delivery systems specifically designed to reach the distal airways more effectively. Ultra-fine particle inhaled corticosteroids, for example, are designed to penetrate deeper into the lung periphery. But their impact on distal Type 2 inflammation in severe asthma requires further study. Combination therapies that target multiple inflammatory pathways, or biologics with improved distal airway penetration, could also offer solutions. The relationship between Type 2 inflammation and other inflammatory phenotypes, such as Type 1 or Type 3, particularly in the distal lung, also warrants further exploration. Some patients with severe asthma exhibit mixed inflammatory patterns, and the distal airways might be a site where these different inflammatory processes converge.

Understanding the precise cellular and molecular mechanisms driving distal airway inflammation in Type 2 severe asthma is essential. Research into the unique epithelial cell responses, immune cell trafficking, and cytokine networks in the small airways could uncover novel therapeutic targets. For instance, the role of specific chemokines in recruiting eosinophils to the distal lung, or the contribution of resident immune cells in maintaining chronic inflammation, are areas of active investigation. The complexity of the distal airway environment suggests that a one-size-fits-all approach to Type 2 severe asthma may be insufficient, and personalized medicine approaches that account for regional differences in inflammation could yield better outcomes. This is a complex area, and the full implications of distal airway involvement are still being mapped out. The ongoing research into epithelial cytokines linking severe asthma to other conditions highlights the intricate nature of these inflammatory pathways.